TipRanks
Opus Genetics (IRD)
NASDAQ:IRD
US Market
IRD
Opus Genetics
RESEARCH TOOLSreports
Want to see IRD full AI Analyst Report?

Opus Genetics (IRD) Stock News & Sentiment

1,358 Followers
Opus Genetics Updates OPGx-BEST1 Trial Data and Outlook
Premium
Company Announcements
Opus Genetics Updates OPGx-BEST1 Trial Data and Outlook
23d ago
8K
IRD
Thomas Shrader Reiterates Buy on IRD, Maintains $12 Price Target Amid Encouraging Clinical and Regulatory Progress
Premium
Ratings
Thomas Shrader Reiterates Buy on IRD, Maintains $12 Price Target Amid Encouraging Clinical and Regulatory Progress
24d ago
IRD
Yun Zhong Reiterates Buy on Opus Genetics, Lifts Price Target to $13 on Higher Probability of Success for OPGx-BEST1 Program
Premium
Ratings
Yun Zhong Reiterates Buy on Opus Genetics, Lifts Price Target to $13 on Higher Probability of Success for OPGx-BEST1 Program
24d ago
IRD
Opus: Encouraging BIRD-1 Data, Expanded BEST1 Opportunity and Solid Cash Position Support Maintained Buy Rating and Unchanged $10 Price Target
Premium
Ratings
Opus: Encouraging BIRD-1 Data, Expanded BEST1 Opportunity and Solid Cash Position Support Maintained Buy Rating and Unchanged $10 Price Target
25d ago
IRD
Opus Genetics Reports Positive OPGx-BEST1 Phase 1/2 Data
Premium
Company Announcements
Opus Genetics Reports Positive OPGx-BEST1 Phase 1/2 Data
25d ago
8K
IRD
Opus Genetics: Buy Rating Reiterated on Upcoming Clinical Catalysts and Solid Cash Runway; $10 Price Target Maintained
Premium
Ratings
Opus Genetics: Buy Rating Reiterated on Upcoming Clinical Catalysts and Solid Cash Runway; $10 Price Target Maintained
1M ago
IRD
Analyst Maintains Buy on Opus Genetics, Reiterates $8 Price Target on Multi-Asset Retinal Disease Pipeline and Upcoming BIRD1 Data
Premium
Ratings
Analyst Maintains Buy on Opus Genetics, Reiterates $8 Price Target on Multi-Asset Retinal Disease Pipeline and Upcoming BIRD1 Data
2M ago
IRD
More IRD News >

IRD News on the Web

Director Foundation Fighting Blindness Retinal Degeneration Fund Sells 556,000 Shares of Opus ...
GuruFocus News
Neutral
Opus Genetics (IRD) Reports Five Early BIRD-1 Responses. Is Phase 3 Planning Justified?
Insider Monkey
Neutral
LifeSci Capital Remains a Buy on Opus Genetics (IRD)
TipRanks News
Bullish
Analysts Offer Insights on Healthcare Companies: Opus Genetics (IRD) and TScan Therapeutics (TCRX)
TipRanks News
Bullish
Opus Genetics: Buy Rating Reiterated on Upcoming Clinical Catalysts and Solid Cash Runway; $10 Price Target Maintained
TipRanks News
Bullish
Longeveron CFO Marie Washburn to switch roles, Nirav Jhaveri to succeed
TipRanks News
Neutral
Is Opus Genetics Inc (IRD) Significantly Overvalued After Q2 Earnings Miss? EPS: -$0. ...
GuruFocus News
Bearish
Analyst Reiterates Buy on Opus Genetics as Pivotal OPGx‑LCA5 Trial Advances and Cash Runway Extends Into 2028
TipRanks News
Bullish

News Score - Last 7 Days

Neutral
IRD
Sector Average
Media Buzz
This Week1 articles
Weekly Average4.5 articles
News Sentiment
This Week50%
Sector Average91%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is IRD’s Media Buzz Sentiment?
1 articles about IRD were published this week. In an average week, 4.5 articles are published.
    What is IRD’s weekly average amount of articles?
    In an average week, 4.5 articles about IRD are published.
      What is IRD’s News Sentiment?
      50% of articles about IRD were positive this week, compared to its sector average of 91%.
        Healthcare Stocks that are Trending in the News
        RHHBYRoche Holding
        BAYRYBayer
        SNYSanofi
        CICigna
        TFXTeleflex
        Showing the stocks with the most bullish news sentiment over the past week